About: Therapeutic and Prophylactic Potential of Small Interfering RNAs against Severe Acute Respiratory Syndrome: Progress to Date

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Therapeutic and Prophylactic Potential of Small Interfering RNAs against Severe Acute Respiratory Syndrome: Progress to Date Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	Therapeutic and Prophylactic Potential of Small Interfering RNAs against Severe Acute Respiratory Syndrome: Progress to Date
Creator	Chang, Zhijie Babiuk, Lorne Hu, Jim
source	Medline; PMC
abstract	Severe acute respiratory syndrome (SARS), caused by the novel coronavirus SARS-CoV, produced a scare when it appeared in 2003 in China and later quickly spread to other countries around the world. Although it has since disappeared, its threat to human health remains. Therefore, studies on the prevention and treatment of SARS are important for dealing with epidemics of this and other infectious diseases. The most promising newly developed technology for intervention in SARS may be RNA interference, an endogenous cellular process for the inhibition of gene expression mediated by sequence-specific double-stranded RNAs. Numerous studies have reported the therapeutic potential of RNA interference for the treatment of various human diseases ranging from cancers to infectious diseases such as HIV and hepatitis. To date, most studies on inhibition of SARS-CoV replication using small interfering RNAs (siRNAs) have been conducted in cell lines in vitro. One study using siRNAs to inhibit SARS-CoV infection in Rhesus macaques demonstrated that siRNAs were effective both prophylactically and therapeutically with no adverse effects in the animals. Challenges remaining for the application of siRNA in vivo for SARS prevention and treatment include the specificity of the siRNAs and the efficiency of delivery. However, with improvements in siRNA design and delivery methods, RNA interference has the potential to become another major weapon for combating dangerous infections due to viruses such as SARS-CoV.
has issue date	2012-08-16(xsd:dateTime)
bibo:doi	10.2165/00063030-200721010-00002
bibo:pmid	17263585
has license	no-cc
sha1sum (hex)	a14318461927b34bd602d055e3bec9dec84015bf
schema:url	https://doi.org/10.2165/00063030-200721010-00002
resource representing a document's title	Therapeutic and Prophylactic Potential of Small Interfering RNAs against Severe Acute Respiratory Syndrome: Progress to Date
has PubMed Central identifier	PMC7099728
has PubMed identifier	17263585
schema:publication	BioDrugs
resource representing a document's body	covid:a14318461927b34bd602d055e3bec9dec84015bf#body_text
is schema:about of	named entity 'siRNAs' named entity 'adverse effects' named entity 'However' named entity 'developed' named entity 'mediated' named entity 'RNAs' named entity 'prevention' named entity 'specificity' named entity 'animals' named entity 'diseases' named entity 'prophylactically' named entity 'prevention' named entity 'RNAs' named entity 'macaques' named entity 'SARS' named entity 'China' named entity 'HIV' named entity 'siRNAs' named entity 'Rhesus macaques' named entity 'hepatitis' named entity 'small interfering RNAs' named entity 'gene expression' named entity 'SARS-CoV' named entity 'viral replication' named entity 'siRNAs' named entity 'SARS' named entity 'rational design' named entity 'regulation of gene expression' named entity 'SARS-CoV' named entity 'animal study' named entity 'gene' named entity 'viral replication' named entity 'RNA' named entity 'siRNAs' named entity 'vector' named entity 'genomic sequence' named entity 'genome' named entity 'plasmids' named entity 'copy number' named entity 'RNAs' named entity 'Rhesus macaques' named entity 'siRNAs' named entity 'viral replication' named entity 'siRNAs' named entity 'SARS-CoV' named entity 'transcription' named entity 'glucose' named entity 'synergistic' named entity 'SARS-CoV' named entity 'siRNA' named entity 'chemical synthesis' named entity 'siRNAs' named entity 'virion' named entity 'vector' named entity 'siRNA' named entity 'gene expression' named entity 'protein' named entity 'siRNA' named entity 'SARS-CoV' named entity 'adverse effects' named entity 'leader sequence' named entity 'interleukin (IL)-8' named entity 'gene expression' named entity 'vector' named entity 'SARS' named entity 'transfected' named entity 'siRNA' named entity 'mutation' named entity 'gene delivery' named entity 'siRNA' named entity 'SARS-CoV' named entity 'virus' named entity 'therapeutic studies' named entity 'nucleotide' named entity 'DNA plasmids' named entity 'protein' named entity 'prophylactic' named entity 'control groups' named entity 'PLpro'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software